TAU researchers discover injectable protein to reverse symptoms of dangerous conditions
The creation of new blood vessels in the body, called “angiogenesis,” is usually discussed in connection with healing wounds and tumors. But it’s also an ongoing process in the female reproductive tract, where the growth and breaking of blood vessels is a normal part of the menstrual cycle. But abnormal growth of blood vessels can have painful consequences and resultant pathologies.
Now, Prof. Ruth Shalgi and research associate Dr. Dana Chuderland of Tel Aviv University‘s Sackler Faculty of Medicine have found a potential treatment for this abnormal growth in a potent physiological anti-angiogentic factor, PEDF. Administered by simple injection, this protein reverses the symptoms of related diseases without compromising fertility, according to pre-clinical studies.
These new findings, which have been reported in the Journal of Clinical Endocrinology and Metabolism, Human Reproduction, and Molecular Human Reproduction, could provide relief for millions of women worldwide. This work was done in collaboration with Prof. Rafael Ron-El and Dr. Ido Ben-Ami from Assaf Harofeh Hospital.
Dangers of angiogenesis
There are two primary pathologies associated with angiogenesis in the female reproductive system. One is endometriosis, characterized by the passage of uterine cells to other locations in the body during menstruation, which causes severe pain and reduced fertility. The other is ovarian hyperstimulation syndrome (OHSS), a possible side effect of IVF treatments. This is a potentially life-threatening disease with symptoms including abdominal pain and swelling.
Approximately 170 million women suffer from endometriosis worldwide, and about 10 percent of women receiving IVF treatment develop OHSS. Because no treatment currently exists for either of these conditions, affected women have no choice but to suffer through the symptoms.
In the past few decades, scientists have conducted extensive research on both pro-angiogenic factors such as VEGF and anti-angiogenic factors including PEDF. The effect of PEDF in decreasing abnormal angiogenesis has been extensively investigated in the eye and in tumors. Prof. Shalgi and Dr. Chuderland hypothesized that the same protein could play a role in diseases of the female reproductive system related to blood vessels growth.
In both OHSS and endometriosis, rampant VEGF levels allow for the abnormal vascularization that characterises both diseases. To counteract this effect and restore a healthy angiogenic balance in the reproductive system, the researchers turned to PEDF as a replacement therapy agent. In the lab, Prof. Shalgi and Dr. Chuderland developed mouse models of both endometriosis and OHSS. After preparing the PEDF protein, they injected the mice with it.
The researchers noted a “perfect reversal” of all symptoms, including reduced abdominal swelling in OHSS-induced mice and eradicated lesions in endometriosis. When evaluating whether this protein might affect fertility, they confirmed that PEDF had no negative impact on ovulation or pregnancy rate. In fact, it increased the number of ovulated eggs in the endometriosis model, suggesting improved fertility.
Easing the pain
The next step is to commercialize the protein for therapeutic use, say the researchers, who were the first to prove that this anti-angiogenic protein is active in the reproductive system. This discovery has been patent protected and is currently undergoing commercialization by Ramot, the technology transfer company of TAU (www.ramot.org).
The Latest Bing News on:
Angiogenesis
- Vitamin D Boosts Gut Bacteria and Enhances Cancer Immunity in Miceon April 27, 2024 at 4:00 am
Vitamin D shows protective effects against cancer in a new study from the Francis Crick Institute, the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) and Aalborg ...
- Compass gets US FDA fast track status for its bispecific DLL4/VEGF-A antibody, CTX-009 in combo with paclitaxel to treat biliary tract cancerson April 26, 2024 at 11:31 pm
Compass gets US FDA fast track status for its bispecific DLL4/VEGF-A antibody, CTX-009 in combo with paclitaxel to treat biliary tract cancers: Boston Saturday, April 27, 2024, 12 ...
- Tobacco Cessation Improves Radiotherapy: What Your Patients Need to Knowon April 26, 2024 at 5:45 am
Smoking cessation is associated with improved treatment responses, reduced side effects, lower risks of secondary cancers, and increased overall survival.
- Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Canceron April 26, 2024 at 5:30 am
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective ...
- New experimental evidence unlocks a puzzle in vascular tissue engineeringon April 25, 2024 at 9:25 am
Angiogenesis is a process of forming hierarchical vascular networks in living tissues. Its complexity makes the controlled generation of blood vessels in laboratory conditions a highly challenging ...
- EyePoint Pharmaceuticals gets grant for treatment of ocular conditions using multi-specific compoundson April 24, 2024 at 6:12 am
Discover the groundbreaking patent by EyePoint Pharmaceuticals for treating ocular conditions with multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists. Treat diabetic ...
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awardson April 23, 2024 at 10:00 pm
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the ...
- Molecular code stimulates pioneer cells to build blood vessels in the bodyon April 17, 2024 at 8:48 am
Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for more than 18 million deaths a year. A team of KIT researchers has now ...
- Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumorson April 16, 2024 at 5:28 am
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who ...
- Thoracoscopic Lobectomy Superior to Open Surgery for NSCLC After Neoadjuvant Therapyon April 14, 2024 at 9:05 pm
Researchers compared perioperative complications and survival outcomes in patients who underwent either VATS or open surgery for NSCLC.
The Latest Google Headlines on:
Angiogenesis
[google_news title=”” keyword=”angiogenesis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
[/vc_column_text]
The Latest Bing News on:
Endometriosis
- Yes, Endometriosis Is Genetic. Here's Why It Matterson April 24, 2024 at 11:33 am
Studies have found that endometriosis affects 10 to 15 percent of women of child-bearing age. And yet, despite how common this disease is — and how utterly debilitating its symptoms can be — we still know far too little about what causes it.
- Hera Biotech Announces Positive Interim Results From Endometriosis Diagnostic Studyon April 23, 2024 at 5:02 am
Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test. Per protocol data from the first 38 patients who have been enrolled in the 60 patient study shows that the diagnostic test is performing with 92% sensitivity,
The Latest Google Headlines on:
Endometriosis
[google_news title=”” keyword=”endometriosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]